Aciclovir 200mg tablets

国: イギリス

言語: 英語

ソース: MHRA (Medicines & Healthcare Products Regulatory Agency)

有効成分:

Aciclovir

から入手可能:

Dowelhurst Ltd

ATCコード:

J05AB01

INN（国際名）:

Aciclovir

投薬量:

200mg

医薬品形態:

Oral tablet

投与経路:

Oral

クラス:

No Controlled Drug Status

処方タイプ:

Valid as a prescribable product

製品概要:

BNF: 05030201

情報リーフレット


























�

製品の特徴

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Aciclovir 200 mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 200 mg tablet contains 200 mg aciclovir.
For the full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Tablet
White to off-white, round (diameter: 9.5 mm), biconvex, uncoated
tablets
debossed with ‘AR 200’ on one side and plain on the other side.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Aciclovir Tablets are indicated for the treatment of herpes simplex
virus
infections of the skin and mucous membranes including initial and
recurrent
genital herpes (excluding neonatal HSV and severe HSV infections in
immunocompromised children).
Aciclovir Tablets are indicated for the suppression (prevention of
recurrences)
of recurrent herpes simplex infections in immunocompetent patients.
Aciclovir Tablets are indicated for the prophylaxis of herpes simplex
infections in immunocompromised patients.
Aciclovir Tablets are indicated for the treatment of varicella
(chickenpox) and
herpes zoster (shingles) infections.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ _
_Dosage in adults _
_ _
Treatment of herpes simplex infections:
200 mg Aciclovir should be taken five times daily at approximately
four
hourly intervals omitting the night time dose. Treatment should
continue for 5
days, but in severe initial infections this may have to be extended.
In severely immunocompromised patients (e.g. after marrow transplant)
or in
patients with impaired absorption from the gut the dose can be doubled
to 400
mg Aciclovir, or alternatively, intravenous dosing could be
considered.
Dosing should begin as early as possible after the start of an
infection; for
recurrent episodes this should preferably be during the prodromal
period or
when lesions first appear.
Suppression of herpes simplex infections in immunocompetent patients:
200 mg Aciclovir should be taken four times daily at approximately
six-hourly
intervals.
Many patients may be conveniently managed on a regimen of 400 mg
Aci